PML-RARa RQ Kits

A reagent kit for detection and quantification of mRNAs of the chimeric PML-RARα bcr1 gene and ABL gene in clinical material by means of polymerase chain reaction (PCR) with real-time hybridization-fluorescence detection.

The kit can be used to detect cases of AML associated with the PML-RARα bcr1 chromosomal rearrangement, to confirm this diagnosis and to monitor the effectiveness of therapy (MRD evaluation).

The kit of reagents is designed to conduct a study in a quantitative format for 24 clinical samples in duplicate (a total of 132 PCR reactions, including controls).

Additional information about the molecular marker:

Acute promyelocytic leukemia (APL, PML, APL) is a variant of acute myeloid leukemia, which in 95% of cases is characterized by a chromosomal translocation t(15;17) (q22; q21), resulting from the fusion of the PML tumor suppressor gene, located on chromosome 15, and the retinoic acid receptor gene RARα on chromosome 17. Expression of the chimeric PML-RARα protein causes inactivation of the normal function of the PML protein and leads to a change in the regulation of the cell cycle and partial blocking of apoptosis, resulting in uncontrolled reproduction of mutant promyelocytes. Therapy with trans-retinoic acid (ATRA) causes deactivation and degradation of the mutant PML-RAR oncoprotein and leads to recovery of patients with ALI in 85-90% of cases.

Three regions of PML gene may be involved in the formation of the t(15;17) translocation: intron 16 (bcr1, 55% of cases), exon 6 (bcr2, 5% of cases), intron 3 (bcr3, 40% of cases), while the breakpoint of the RARPML-RARα gene is always located in the second intron. As a result, three isoforms of the chimeric gene can arise: long (bcr1, L), medium (bcr2, V), and short (bcr3, S).

Figure 1. Arrangement of chimeric transcripts PML-RARα (bcr1, bcr2, bcr3). The binding sites of primers and probes for real-time PCR are marked. The positions of primers and probes are indicated relative to the 5' end of the nucleotide sequences of normal transcripts.

PML-RARα chimeric transcripts are found in most cases of APL and are a marker for the detection of APL cells in the diagnosis and monitoring of the minimal residual disease. The detection of PML-RARα is a marker of a favorable disease prognosis when adequate therapy is applied.

More detailed information on diagnostic approaches, frequency of the study and prognostic value of this testing in leukemias are available on the website of the International Network European Leukemia Net (http://www.leukemia-net.org).

Ordering information:

PML-RARA bcr 1 transcripts, RQ Kit, 24 tests                                                               Cat.No RQ-6-24

PML-RARA bcr 2 transcripts, RQ Kit, 24 tests                                                              Cat.No RQ-7-24

PML-RARA bcr 3 transcripts, RQ Kit, 24 tests                                                               Cat.No RQ-8-24

Additiional reagents:

TriZ Reagent Kit                                                                                                              Cat.No RK-100

ReverZyme Kit                                                                                                                Cat.No RT-1

Price: on request 

Reagents are for research use only (RUO)